Metal Segment, by Material to Account Largest Joint Resurfacing Devices Market Share during 2025-2031

According to our new research study on "Joint Resurfacing Devices Market Forecast to 2031 - Global Analysis - by Type, Material, and End User," the market was valued at US$ 2.35 billion in 2024 to US$ 3.25 billion by 2031; the market is expected to register a CAGR of 4.9% during 2025-2031. The joint resurfacing devices market growth is attributed to the demographic aging and the global osteoarthritis epidemic. Additionally, advancements in minimally invasive techniques and innovation in next-generation implants contribute to the joint resurfacing devices market growth.

Technological improvements in minimally invasive surgery (MIS) techniques and implant designs are helping to speed up recoveries, decrease complications, increase the number of patients who can be treated, thus, the use of these implants is being preferred over traditional open procedures. The innovations such as posterior MIS approaches and uncemented metal-on-metal implants have made it possible for resurfacing to be done as a viable outpatient option that minimizes tissue trauma and postoperative morbidity, and at the same time, preserves natural joint kinematics. Patients, mostly younger than 65 years and suffering from OA (66% of cases), reached 95% satisfaction among those who had been to the hospital before, which proves that MIS is better in patient-centered outcomes.

Blood loss has also been reduced by 22% (98 mL vs. 127 mL) in knee resurfacing through MIS total knee arthroplasty (TKA) as compared to the conventional method, however, hospital stays were on average three days in both cases, and there were no differences in 12-week functional scores such as timed-up-and-go tests. Examples are suture-stabilized arthrotomies that do not allow patellar eversion thus, at the same time, restraining extensor disruptions and promoting early quadriceps activation which is very important for the resurfacing that is the bone-sparing concept.

Broader applications such as AI-augmented reality (AR) systems like the Tianji robot have made it possible for China to perform more than 30,000 precise resections, thus accuracy in lesion targeting for OA and avascular necrosis has been improved. These technologies are leading to market growth by dramatically lowering the costs and thus, making the procedure available to more people, as is the case in programs with insurers such as Blue Cross Blue Shield, where outpatient HRA saves 33-61% ($13,000-$41,000 per case) compared to inpatient arthroplasty.

For patients who are active, the example of posterior-stabilized mobile-bearing implants in MIS TKA shows how reduced tourniquet times and hematoma rates can allow a quicker return of the patient to normal activities, while at the same time, radiographic alignments are within 3